| dc.creator | Papatheodoridis G.V., Goulis J., Sypsa V., Lionis C., Manolakopoulos S., Elefsiniotis I., Anagnostou O., Tsoulas C., Hatzakis A., Dalekos G.N. | en |
| dc.date.accessioned | 2023-01-31T09:44:53Z | |
| dc.date.available | 2023-01-31T09:44:53Z | |
| dc.date.issued | 2019 | |
| dc.identifier | 10.20524/aog.2019.0375 | |
| dc.identifier.issn | 11087471 | |
| dc.identifier.uri | http://hdl.handle.net/11615/77861 | |
| dc.description.abstract | There are estimated to be 74,000-134,000 patients living with chronic hepatitis C in Greece, but only 20-30% of them are aware of their disease status. In July 2017, the Hellenic National Plan for Hepatitis C was announced in alignment with the World Health Organization goals for the eradication of hepatitis C virus (HCV) by the year 2030. This article discusses the epidemiology and current treatment of chronic hepatitis C in Greece. Additionally the authors propose actions on how to bring back to care diagnosed patients lost to follow up, optimize access to care for HCV-infected people who inject drugs, and increase HCV screening in the general population. The medical community in Greece can play a pivotal role in the implementation of the HCV National Plan and in the efforts to reach the goal of HCV elimination. © 2019 Hellenic Society of Gastroenterology. | en |
| dc.language.iso | en | en |
| dc.source | Annals of Gastroenterology | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069701850&doi=10.20524%2faog.2019.0375&partnerID=40&md5=0b6c0c7afa7d41618fc15731d33befff | |
| dc.subject | antivirus agent | en |
| dc.subject | elbasvir plus grazoprevir | en |
| dc.subject | glecaprevir plus pibrentasvir | en |
| dc.subject | ledipasvir plus sofosbuvir | en |
| dc.subject | nonstructural protein 5A inhibitor | en |
| dc.subject | ombitasvir plus paritaprevir plus ritonavir | en |
| dc.subject | ribavirin | en |
| dc.subject | sofosbuvir plus velpatasvir | en |
| dc.subject | sofosbuvir plus velpatasvir plus voxilaprevir | en |
| dc.subject | Article | en |
| dc.subject | beta thalassemia | en |
| dc.subject | chronic hepatitis C | en |
| dc.subject | disease elimination | en |
| dc.subject | disease severity | en |
| dc.subject | enzyme linked immunosorbent assay | en |
| dc.subject | follow up | en |
| dc.subject | general practitioner | en |
| dc.subject | genotype | en |
| dc.subject | Greece | en |
| dc.subject | hemoglobinopathy | en |
| dc.subject | Hepatitis C virus | en |
| dc.subject | high risk population | en |
| dc.subject | human | en |
| dc.subject | liver cirrhosis | en |
| dc.subject | liver disease | en |
| dc.subject | mass screening | en |
| dc.subject | morbidity | en |
| dc.subject | mortality | en |
| dc.subject | opiate substitution treatment | en |
| dc.subject | patient care | en |
| dc.subject | prevalence | en |
| dc.subject | primary health care | en |
| dc.subject | sustained virologic response | en |
| dc.subject | transient elastography | en |
| dc.subject | viral clearance | en |
| dc.subject | viremia | en |
| dc.subject | virus load | en |
| dc.subject | Hellenic Society of Gastroenterology | en |
| dc.title | Aiming towards hepatitis C virus elimination in Greece | en |
| dc.type | journalArticle | en |